VCG
IONS icon

Vantage Consulting Group’s Ionis Pharmaceuticals IONS Stock Holding History

Vantage Consulting Group’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-17
Closed -$1K – 806
2020
Q4 		$1K Buy
+17
New +$847 ﹤0.01% 1762

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vantage Consulting Group's IONS Position: Q1 2021 in Review

Vantage Consulting Group sold out of Ionis Pharmaceuticals (IONS) in Q1 2021, closing a stake of 17 shares — an estimated $1K sold.

Vantage Consulting Group first reported a position in IONS in Q4 2020 and held it in 1 quarter. The position peaked at $1K in Q4 2020. 364 funds tracked by Wall St. Rank hold IONS as of Q1 2021.

  • Vantage Consulting Group reported no remaining Ionis Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Vantage Consulting Group sold 17 Ionis Pharmaceuticals shares in Q1 2021, an estimated $1K.
  • Vantage Consulting Group first reported a position in Ionis Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Vantage Consulting Group's Ionis Pharmaceuticals position peaked at $1K in Q4 2020.
  • 364 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2021.

Based on Vantage Consulting Group's 13F filing for Q1 2021, filed 14 May 2021.